Racura Oncology - Public Comps and Valuation Multiples

Racura Oncology Overview

About Racura Oncology

Racura Oncology Ltd is a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care. Racura's primary asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that functions by binding to G4-DNA and RNA, resulting to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent researchs made by the company have enabled composition of matter IP filings that provide for 20 years of patent protection over RCDS1. Racura is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications.

Founded

2011

HQ

Employees

n/a

Website

racuraoncology.com

Sectors

Drug Development & Therapeutics
Small Molecules
BioTech
DeepTech

Financials

LTM Revenue $1.8M

LTM EBITDA -$4.2M

EV

$269M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Racura Oncology Financials

As of January 2026, Racura Oncology reported last 12-month revenue of $1.8M and EBITDA of -$4.2M.

In the same period, Racura Oncology achieved -$4.1M in LTM net income.

See Racura Oncology valuation multiples based on analyst estimates

Racura Oncology P&L

In the most recent fiscal year, Racura Oncology reported EBITDA of -$7.3M.

Racura Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Racura Oncology valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$1.8M	XXX	n/a	XXX	XXX	XXX
Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
Gross Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA	-$4.2M	XXX	-$7.3M	XXX	XXX	XXX
EBITDA Margin	-236%	XXX	n/a	XXX	XXX	XXX
EBIT	-$4.4M	XXX	-$7.5M	XXX	XXX	XXX
EBIT Margin	-246%	XXX	n/a	XXX	XXX	XXX
Net Profit	-$4.1M	XXX	-$3.3M	XXX	XXX	XXX
Net Margin	-228%	XXX	n/a	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Racura Oncology including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $1.8M. EBITDA for the last twelve months was -$4.2M.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$1.8M	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	NaN% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$4.2M	Analyst estimates available to subscribers	-$7.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-236.3% EBITDA margin	Analyst estimates available to subscribers	NaN% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$4.4M	Analyst estimates available to subscribers	-$7.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-245.9% EBIT margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$4.1M	Analyst estimates available to subscribers	-$3.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-228.4% net profit margin	Analyst estimates available to subscribers	NaN% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Racura Oncology

This financial data table provides comprehensive performance metrics for Racura Oncology, a company based in Australia. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Racura Oncology generated $1.8M in revenue over the last twelve months.
The company achieved -$4.2M in EBITDA over the last twelve months.
Net income over the last twelve months reached -$4.1M.

Fiscal Year Performance

Fiscal year EBITDA was -$7.3M.
The company maintained a gross profit margin of NaN% in the most recent fiscal year.
EBITDA margin for the fiscal year was NaN%.
Net profit margin reached NaN% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Racura Oncology. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Racura Oncology Stock Performance

Racura Oncology has current market cap of AUD 404M (or $279M), and EV of AUD 391M (or $269M).

Market Cap Evolution

Racura Oncology Stock Data

As of January 30, 2026, Racura Oncology's stock price is AUD 2 (or $2).

See Racura Oncology trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$269M	$279M	XXX	XXX	XXX	XXX	$-0.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Racura Oncology Valuation Multiples

Racura Oncology's trades at n/a EV/Revenue multiple, and -44.5x EV/EBITDA.

See valuation multiples for Racura Oncology and 15K+ public comps

Racura Oncology Financial Valuation Multiples

As of January 30, 2026, Racura Oncology has market cap of $279M and EV of $269M.

Equity research analysts estimate Racura Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Racura Oncology has a P/E ratio of -67.9x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$279M	XXX	$279M	XXX	XXX	XXX
EV (current)	$269M	XXX	$269M	XXX	XXX	XXX
EV/Revenue	150.0x	XXX	n/a	XXX	XXX	XXX
EV/EBITDA	-63.5x	XXX	-44.5x	XXX	XXX	XXX
EV/EBIT	-61.0x	XXX	-43.3x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	-67.9x	XXX	-68.0x	XXX	XXX	XXX
EV/FCF	-67.8x	XXX	-68.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Racura Oncology Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Racura Oncology Margins & Growth Rates

Racura Oncology's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Racura Oncology's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Racura Oncology's rule of X is -236% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Racura Oncology and other 15K+ public comps

Racura Oncology Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	-236%	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	114%	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	-236%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	n/a	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial